Aussie jobs to go after trial failure

The need to abandon a clinical trial has seen ASX-listed Chimeric Therapeutics hit hard times with cost-cutting and job losses on top of pivoting to a different technology to treat gastrointestinal cancers as the biotech shops around for a buyer.